Announcement on Voluntary Disclosure of the Completion of First Patient Enrollment and Dosing in the Phase Ib Clinical Trial of Innovative Drug AA001 Monoclonal Antibody for Alzheimer’s Disease by an Joint-stock Company
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment